anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hepatocellular carcinoma (HCC) continues to play a substantial role in cancer-related morbidity and mortality, largely owing to its pronounced tumor heterogeneity and propensity for recurrence. This underscores the pressing need for in-depth examination of its highly malignant mechanisms. Annexin A5 (ANXA5), recognized as a hallmark tumor protein, has emerged as a focal point of interest because of its ambiguous function and mechanism in HCC prognosis. This study aimed to provide a comprehensive understanding of the role of ANXA5 in the malignant progression of human HCC cells by employing an integrative approach that combines conventional experimental methods with RNA sequencing.
METHODS: Differences in ANXA5 expression between HCC tissues and corresponding nontumor tissues were evaluated using immunofluorescence (n = 25). Correlation analysis was subsequently performed to assess the association between ANXA5 expression and clinicopathological features (n = 65). The role of ANXA5 in human HCC cell lines with ANXA5 gene knockout and overexpression was explored in vitro using migration and invasion assays and Ki-67 indices and in vivo based on node mice xenograft model. A tube formation assay using human umbilical vein endothelial cells (HUVECs) was conducted to demonstrate the angiogenic effects of ANXA5 in HCC. Single-cell and bulk RNA sequencing was used to further investigate the underlying mechanisms involved.
RESULTS: This study revealed that ANXA5 is highly expressed in patients with HCC and correlates with poor prognosis. Assays for migration, invasion, and proliferation based on ANXA5 gene knockout and overexpression systems in human HCC cell lines have demonstrated that ANXA5 enhances HCC malignancy in vitro and in vivo. Tube formation assays of HUVECs indicated that ANXA5 facilitates angiogenesis and recruits endothelial cells to HCC cells. Single-cell and bulk RNA sequencing data analysis further confirmed that ANXA5 expression in HCC is associated with hepatocyte metabolism, immune response activation, and various oncogenic signaling pathways.
CONCLUSIONS: This study revealed a meaningful association between elevated ANXA5 expression in tumor tissues and an unfavorable prognosis in patients with HCC. In addition, ANXA5 promotes HCC malignancy by promoting invasion and angiogenesis. Thus, ANXA5 has emerged as a promising therapeutic target for HCC and has the potential to improve patient outcomes.
OBJECTIVE: In the present study, we aimed to explore the association between left atrial appendage emptying velocity (LAAEV) measured by transesophageal echocardiography and atrial fibrillation (AF) recurrence after radiofrequency catheter ablation (RFCA) in patients with early persistent atrial fibrillation (PeAF).
METHODS: We retrospectively analyzed patients with early PeAF who underwent their initial ablation procedure. The echocardiographic and clinical data of the enrolled patients were collected and recorded prior to the operation. Following adjustment for confounding factors, we investigated the relationship between the LAAEV and AF recurrence in patients with early PeAF after radiofrequency ablation.
RESULTS: The proportions of AF recurrence in the low, medium, and high LAAEV groups were 48.8%, 16.0%, and 13.1%, respectively. After adjusting for potential confounding factors, we observed a gradual decrease in the risk of AF recurrence with increasing LAAEV (odds ratio: 0.882, 95% confidence interval: 0.842-0.924, p<0.001). This trend was statistically significant (p<0.001), particularly when comparing the high and low LAAEV groups (odds ratio: 0.033, 95% confidence interval: 0.009-0.116, p<0.001). Curve fitting analysis demonstrated an approximate negative linear association between LAAEV and the probability of AF recurrence.
CONCLUSIONS: Among patients with early PeAF who successfully underwent their first RFCA, we found that the LAAEV within 24 h before the procedure was independently correlated with the risk of AF recurrence. Notably, this association was negative, indicating that higher LAAEV was associated with a lower risk of AF recurrence.
Women with GDM diagnosed early (\< 20 weeks gestation) or with routine 3rd trimester screening (\>=24 weeks) will be enrolled in this longitudinal study. All enrolled women will complete a oral glucose tolerance test and wear a continuous glucose monitor for 10 days at the 3 designated study time points (0-4 days, 4-6 weeks, and 6 months after delivery).
Subjects will receive a placebo starch, consisting of non resistant starch and be instructed to take 2 tablespoons (\~ 20 grams) twice daily for 14 days. Initially subjects will take 2 tablespoons once daily for the first three days.
The overall objectives of this study are to understand the factors leading to continued incidence of leprosy in the Philippines by novel molecular methodologies using a combination of retrospective and prospective sampling approaches. The overall objectives include: (1) strain typing of M. leprae isolates obtained from new and relapsed leprosy patients in the Philippines to identify clusters and transmission patterns when combined with conventional epidemiological criteria; (2) to determine the viability of M. leprae by mRNA detection in specimens collected from new patients; and those with signs of relapse; (3) to identify and determine the extent of mutations conferring resistance in past and circulating M. leprae isolates from leprosy patients to two Multidrug therapy (MDT) drugs; Dapsone and Rifampicin and; (4) to detect chains of transmission in endemic populations by a retrospective analyses of isolates in sample banks when combined with strain typing information from new cases and conventional epidemiological criteria. The following are the outcome measures for each of the objectives: (1) strain typing: identification of genotypes; (2) percent of samples from patients and their contacts containing viable M. leprae (as judged by the presence of mRNA for a panel of M. leprae genes; (3) percent of samples from patients and their contacts containing mutations in M. leprae rpoB and folP 1 genes and identification of new mutations associated with relapse and; (4) identification of matching or similar genotypes in new samples obtained from patients and their household contacts with those in retrospective samples. Clinical specimens that contain M. leprae bacilli such as skin biopsy, slit skin smears, nasal swabs and blood are required to obtain M. leprae DNA to meet the objectives of the study. Nasal swabs will be used for assessing the role of the nasal mucosa in infection and dissemination in leprosy. The blood is useful for monitoring the humoral responses to infection. Skin biopsy, slit skin smears, nasal swabs and blood will be obtained from informed consenting patients. Enrollment and sample collection procedures will take approximately 1-2 hours. These procedures will be performed during the patient's visit to the clinic for diagnosis and therapy for leprosy. As part of the study, a punch biopsy from a lesion is being collected to enable sufficient quantities of DNA to be extracted for strain typing, a critical objective of this study. Patients will be required to visit the site once more after 7-10 days to assess the biopsy site. This visit may take 30-60 minutes. An epidemiology survey containing demographic and clinical information will be obtained from each participant. Study participants for prospective sample collections will include volunteering and consenting individuals, 18 years old and above, reporting at Leonard Wood Memorial (LWM) CebuSkin Clinic, Leonard Wood Memorial Center for Biomedical Research, Cebu, Philippines for the diagnosis of leprosy and/or relapse of leprosy.
Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine-2,6-dione,3,7-dihydro-1,3-dimethyl-, and is represented by the following structural formula:

The molecular formula of anhydrous theophylline is C7H8N4O2 with a molecular weight of 180.17.

Each extended-release capsule, for oral administration, contains 125 mg, 200 mg, or 300 mg anhydrous theophylline in the form of long-acting beads within a dye-free hard gelatin capsule. In addition, each capsule contains the following inactive ingredients: black iron oxide, butylparaben, castor oil, edetate calcium disodium, ethylcellulose, gelatin, methylparaben, pharmaceutical glaze, povidone, propylparaben, sodium lauryl sulfate, sodium propionate, starch, sugar spheres, and talc. The 200 mg, and 300 mg capsules also contain titanium dioxide.

This extended-release capsule formulation can be administered with a 12-hour dosing interval for a majority of patients and a 24-hour dosing interval for selected patients (see DOSAGE AND ADMINISTRATION).

These capsules comply with USP Drug Release Test 10.
A booster and activator composition enhances tooth-whitening agents, in particular hydrogen peroxide. The composition for boosting and activating peroxides in tooth whiteners includes a heavy-metal salt solution and a chelator for preventing the heavy-metal salt solution from precipitating. The heavy-metal salt solution preferably includes manganese coordinate complexes, in particular, manganese gluconate. The chelator preferably is tetrasodudium Ethylenediamine Tetra-acetic Acid (EDTA). The composition also includes a desensitizing/adhering agent such as polyvinylpyrrolidone (PVP). The composition also includes a wetting agent such as Miranol Ultra. The composition is pH adjusted to a basic pH, preferably above 10.5.
Of the total number of patients with relapsed or refractory multiple myeloma in clinical studies of SARCLISA, 56% (n=586) were 65 years of age and older, while 16% (n=163) were 75 years of age and older [see Clinical Studies (14)]. No overall differences in safety or effectiveness were observed between patients 65 years of age and older compared to younger patients, and other reported clinical experience has not identified differences in responses between the adults 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Of the total number of SARCLISA-treated patients with newly diagnosed multiple myeloma in IMROZ, 72% (n=319) were less than 75 years of age and 28% (n=125) were 75 years of age and older. The clinical trial did not enroll patients over age 80 [see Clinical Studies (14)]. Adverse reactions occurring at a higher frequency in the SARCLISA arm (≥5%) in patients 75 years of age and older included neutropenia. Adverse reactions leading to dose modifications in patients 75 years of age and older occurred at a higher frequency (≥5%) in the SARCLISA arm. The hazard ratio for overall survival (OS) in patients 75 years of age and older was 1.25 [95% CI: 0.68 to 2.3].
Patients randomized into this group were received pars plana vitrectomy surgery with silicone oil tamponade and without internal limiting membrane peeling. And silicone oil tamponade was removed at least 12 months after the primary surgery with completely resolved of foveoschisis.
PURPOSE:To obtain CSF, by multiplying an established cell producing CSF derived from fibrosarcoma to cause graunloblastosis until the established cell reaches confluent and changing a culture solution intermittently, so that the cell exists. CONSTITUTION:An established cell capable of producing CSF derived from fibrousarcoma to granuloblastosis is subjected to primary culture, and the establised cell reaches confluent. Then, the cell having reached confluent is treated with 0.2% trypsin, made into a single cell dispersed state, and subjected to subculture. The established cell producing CSF, having repeated several generations of the subculture is cloned, to give the established clone cell producing highly CSF. The established cell exists for a long period in a protein-free medium without passage of cell, continues to produce CSF with high concentration, and the culture solution contains granulocyte CSF and monocyte CSF. Both the CSF can be purifid and separated. Therefore, it has a wide use and is effective for mammals including mouse.
FIELD: hygiene.SUBSTANCE: group of inventions relates to oral care. Composition for oral care, where all ingredients are suitable for use in the oral cavity, contains from 0.2 to 1.5 % of potassium peroxymonosulphate in terms of total weight of the oral care composition, from 10 to 40 wt. % of polyvinylpyrrolidone in terms of total weight of oral care composition, from 20 to 60 wt. % of liquid poloxamer in terms of total weight of oral care composition and from 1 to 40 wt. % of copolymer polyethylene/polypropylene glycol in terms of total weight of oral care composition, wherein the polyvinylpyrrolidone is a cross-linked polyvinylpyrrolidone (PVP), wherein the moisture content of the oral care composition is 5 wt. % or less in terms of the total weight of the oral care composition. Also disclosed is a method for teeth surface whitening.EFFECT: group of inventions provides active oxygen stability and bleaching efficiency.7 cl, 1 dwg, 5 tbl, 1 ex
INTRODUCTION: To evaluate whether epidural analgesia is an independent risk factor for OASIS.
METHODS: A population-based cohort study including all women who delivered by spontaneous vaginal delivery or by instrumental delivery beyond 24 weeks gestation was conducted. Deliveries occurred between 1988 and 2016 at a large university tertiary medical center. Women with multiple gestations and those lacking prenatal care were excluded from the analysis.
RESULTS: During the study period, 252,542 women delivered at the Soroka University Medical Center and met the inclusion criteria. Of these, 583 (0.23%) were diagnosed with OASIS. Women with OASIS were more likely to be younger, nulliparous, with suspected fetal macrosomia, had higher rates of labor induction and vacuum extraction delivery, higher rates of conceiving after infertility treatments, more advanced gestational age at delivery, higher mean birth weight, higher rates of post-partum hemorrhage and need for blood transfusions. Use of epidural analgesia during pregnancy was significantly high among the OASIS group. Rates of episiotomy were not significantly different between the groups. Using a multimodal logistic regression model, after controlling for vacuum delivery, large for gestational age, nulliparity, gestational age, ethnicity, maternal age, induction of labor, fertility treatments, non-reassuring fetal heart rate and non-progressive second stage of labor, epidural analgesia was found to be significantly associated with OASIS.
CONCLUSION: Epidural analgesia was found to be an independent risk factor for OASIS in our population.
NEW MATERIAL:A compound shown by the formulaI(R is alkyl). EXAMPLE:11-O-Methylerythromycin A. USE:An antibacterial agent showing improved antibacterial activity in living body. PROCESS:For example, a compound (e.g., O,N-dibenzyloxycarbonyl-des-N-methyl- erythromycin A, etc.) shown by the formula II (Z is H or benzylcarbonyloxy) is reacted with an alkylating agent (e.g., methyl iodide, etc.) in the presence of a base such as sodium hydride, etc. so that the hydroxyl group at 11 position of erythronolide ring is alkylated, to give a compound shown by the formula III (R is alkyl), which is isolated and purified. The isolated compound is reduced catalytically, the protecting group Z is eliminated, and reduced catalytically in the presence of excess formaldehyde, so that it is N-methylated, to give a compound shown by the formulaI.
A mechanism is provided to implement a health risk assessment system for adaptively and dynamically generating a personalized questionnaire for health risk assessment of a patient. A set of responses are analyzed and a patient is grouped to an initial group that matches a similar patient group. Utilizing the initial group, an initial question is selected to present to the patient. Responsive to receiving a current response to the initial question, the current response is analyzed, the patient is grouped to a next group, and a next question is identified and presented to the patient. The process continues until a last group is reached where a scoring of possible health risks associated with the patient is performed based on each response provided by the patient and identified groupings. A final possible health risk or ranked set of possible health risks is then presented based on the scoring.
Typical treatment for testicular cancer that has spread to the retroperitoneum is chemotherapy, radiation therapy, or surgery. Chemotherapy and radiation therapy have numerous side effects and long-term complications and open retroperitoneum lymph node dissection (RPLND), the typical surgical approach for advanced testicular cancer, can be invasive and is fairly morbid. This study will investigate the safety and efficacy of using robotic retroperitoneal lymph node dissection (R-RPLND), a minimally invasive surgical approach, as the first-line of treatment for stage IIA/B (or equivalent) seminoma patients. R-RPLND will be trialed as an alternative to chemotherapy, radiation therapy (for seminoma patients) and open RPLND in this study. The primary endpoint of this study is Relapse Free Survival (RFS) at 2 years and 5 years. Secondary endpoints of this study include characteristics of relapse, time to progression, percentage of patients that can avoid chemotherapy and radiation therapy after R-RPLND, perioperative, short-term and long-term complications, rate of retrograde ejaculation, time to return of ejaculation and return to work. Additionally, Quality of Life will be measured by a questionnaire administered at 4 months post-RPLND. Approximately 25 patients will be enrolled in this study and will be followed for at least 5 years.

The data will provide important insights into the safety and efficacy of performing R-RPLND for seminoma patients with stage IIA/B (or equivalent) disease. This information will be paramount to informing clinical practice and patterns of care for treating advanced seminoma and use of the robotic approach for RPLND.
1458898 Anilides SCIENCE UNION ET CIE SOC FRANCAISE DE RECHERCHE MEDICALE 18 March 1975 [18 March 1974] 11868/74 Heading C2C The invention comprises anilides of the Formula I in which n is 0 to 3; R is H or C 1-6 alkyl, C 2-6 alkenyl or p optionally substituted phenyl- C 1-4 -alkyl; R 2 is C 1-6 alkoxy, C 1-6 alkylthio, halogen or trifluoromethoxy; R 3 and R 4 each are H or C 1-6 alkyl; X and Y each are H or C 1-6 alkyl, or X and Y together with the nitrogen atom to which they are attached form a 3 to 7 membered saturated heterocyclic ring which may contain one or two further heteroatoms, or X and R 3 together with the intervening atoms form a 5 to 7 membered saturated heterocyclic ring, or X and R 4 together with the intervening atoms form a 4 to 6 membered saturated heterocyclic ring which may contain one or two further heteroatoms; and A and B each are H, C 1-6 alkyl. C 1-18 carboxylic acyl, or A and B are both oxygen, or A and B together with the nitrogen atom to which they are attached form a 3 to 7 membered saturated heterocyclic ring and physiologically tolerable acid addition salts thereof. The compounds are prepared by reacting anilines of the Formula II with amino acids of the formula or with reactive functional derivatives thereof, if desired, when R 2 is halogen in the resulting anilides, reacting the products with metal cyanides, alkali metal mercaptides, alkali metal alkoxides or alkali metal trifluoromethoxides, and, if desired, reducing the nitro group. Compounds of Formula I above in which A and B are alkyl or acyl or together with N atom form a saturated heterocyclic ring are obtained by alkylating or acylating the corresponding compounds in which A and B are hydrogen. The compounds may also be prepared by reacting compounds of the formula wherein Z is an arylsulphonyloxy, C 1-6 alkyl sulphonyloxy, trialkylsilyloxy or halogen with amines of the formula and, if desired, reducing the nitro-groups thereof. 3,5<SP>1</SP> - Dichloro - 4<SP>1</SP> - nitropropion - o - anisidide is obtained by reacting 5-chloro-4-nitro-oanisidine with 3-chloropropionyl chloride. Pharmaceutical compositions, suitable for oral, parenteral, rectal, perlingual or percutaneous administration, contain the above anilides or physiologically tolerable acid addition salts thereof in admixture or conjunction with inert pharmaceutical excipients. The compounds possess an inhibitory effect on gastric secretion.
[GB1458898A]
Compounds with unique liphagane meroterpenoid scaffold having boronic acid functionality in the skeleton are described [formula 1] together with pharmacological potential of these compounds as anticancer agents. A method of preparation and inhibiting the activity of phosphoinositide-3-kinase (PI3K-alpha and beta) has been presented. In particular, the invention describes a method of inhibiting PI3K isoforms, wherein the compounds are novel structures based on liphagane scaffold with unique boronic acid functionality. The methods and uses thereof are described herein this invention. The claimed Markush formula is: [Formular 1]. Y can be O, NH, NR, S; Representative compounds are: [Compounds A, B, C, D]
Autoimmune diseases are the result of an immune response directed against a self antigen. Susceptibility to an autoimmune disease is conferred by antigen encoded within an allele of the MHC. A potentially susceptible individual is protected from developing the autoimmune disease by an antigen encoded within a second allele of the MHC. Individuals who have the allele for susceptibility, and lack the allele for protection are highly susceptible to manifestation of the autoimmune disease. The present invention provides a method for prophylactically treating individuals who are highly susceptible to an autoimmune disease. In the method, the individuals are tolerized by administration of a protective antigen encoded within the protective allele. As part of the invention, the sequences encoding the protective antigen(s), as well as the antigen(s) conferred susceptibility, are elucidated. The elucidation of these sequences allows for the synthesis of the antigens conferring these traits. These antigens may be used pharmacologically; in addition, they may be used to raise monoclonal antibodies. Monoclonal antibodies to these antigens are useful in diagnosis of susceptibility, and in elucidating the mechanisms by which antigens control the manifestation of the autoimmune disease. In addition, the sequence data allows the synthesis of nucleotide probes which are useful in diagnosis of susceptibility to the autoimmune disease.